[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.200.74. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
November 2017

Demystifying Neurosarcoidosis and Informing Prognosis

Author Affiliations
  • 1Multiple Sclerosis and Neuroinflammation Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco
JAMA Neurol. 2017;74(11):1296-1298. doi:10.1001/jamaneurol.2017.1473

Sarcoidosis has developed an almost legendary mystique among neurologists that is rooted in our limited understanding of the disease. The unknowns are daunting: the precise etiology of sarcoidosis remains unresolved, the factors that drive neurologic organ system involvement remain unclear, the diagnosis can be challenging to confirm in the nervous system, and the potential clinical manifestations of neurosarcoidosis (NS) are often alleged to be protean. Neurosarcoidosis is commonly considered in the differential diagnosis of patients with unexplained neurologic symptoms and clinical deficits, so much so that a tired aphorism is that no differential diagnosis is complete without consideration of sarcoidosis. This situation is not without consequence. Among neuroinflammatory disorders, diagnostic workups for NS account for a disproportionately large share of total inpatient costs,1 and tremendous variability in clinical practice exists regarding application of various proposed diagnostic criteria.2,3 Particularly in the absence of histopathologic findings, this can lead in some cases to premature or unwarranted diagnosis of NS.

×